

## Higher dose corticosteroids for COVID-19

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

# **Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial**

**Running title:** Higher dose corticosteroids for COVID-19

### **RECOVERY Collaborative Group\***

\*The Writing Committee and Trial Steering Committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: [recoverytrial@ndph.ox.ac.uk](mailto:recoverytrial@ndph.ox.ac.uk)

## Higher dose corticosteroids for COVID-19

### 23 **SUMMARY**

24 **Background:** Low-dose corticosteroids (e.g. 6 mg dexamethasone) have been shown  
25 to reduce mortality for hypoxic COVID-19 patients. We have previously reported that  
26 higher dose corticosteroids cause harm in patients with hypoxia but not receiving  
27 ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation  
28 or extra-corporeal membrane oxygenation), but the balance of efficacy and safety in  
29 patients receiving ventilatory support is uncertain.

30 **Methods:** This randomised, controlled, open-label platform trial (Randomised  
31 Evaluation of COVID-19 Therapy [RECOVERY]) assessed multiple possible treatments  
32 in patients hospitalised for COVID-19. Eligible and consenting adult patients receiving  
33 ventilatory support were randomly allocated (1:1) to either usual care with higher dose  
34 corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once  
35 daily for 5 days or until discharge if sooner) or usual standard of care alone (which  
36 includes dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The  
37 primary outcome was 28-day mortality; secondary outcomes were duration of  
38 hospitalisation and (among participants not on invasive mechanical ventilation at  
39 baseline) the composite of invasive mechanical ventilation or death. Recruitment closed  
40 on 31 March 2024 when funding for the trial ended. The RECOVERY trial is registered  
41 with ISRCTN (50189673) and [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04381936).

42 **Findings:** Between 25 May 2021 and 9 January 2024, 477 COVID-19 patients receiving  
43 ventilatory support were randomly allocated to receive usual care plus higher dose  
44 corticosteroids versus usual care alone (of whom 99% received corticosteroids during the  
45 follow-up period). Of those randomised, 221 (46%) were in Asia, 245 (51%) in the UK and

## Higher dose corticosteroids for COVID-19

46 11 (2%) in Africa. 143 (30%) had diabetes mellitus. Overall, 86 (35%) of 246 patients  
47 allocated to higher dose corticosteroids versus 86 (37%) of 231 patients allocated to usual  
48 care died within 28 days (rate ratio [RR] 0.87; 95% CI 0.64-1.18;  $p=0.37$ ). There was no  
49 significant difference in the proportion of patients discharged from hospital alive within 28  
50 days (128 [52%] in the higher dose corticosteroids group vs 120 [52%] in the usual care  
51 group; RR 1.04, 0.81-1.33];  $p=0.78$ ). Among those not on invasive mechanical ventilation  
52 at baseline, there was no significant difference in the proportion meeting the composite  
53 endpoint of invasive mechanical ventilation or death (76 [37%] of 206 vs 93 [45%] of 205;  
54 RR 0.79 [95% CI 0.63–1.00];  $p=0.05$ ).

55 **Interpretation:** In patients hospitalised for COVID-19 receiving ventilatory support, we  
56 found no evidence that higher dose corticosteroids reduced the risk of death compared  
57 to usual care, which included low dose corticosteroids.

58 **Funding:** UK Research and Innovation (Medical Research Council) and National Institute  
59 of Health Research (Grant ref: MC\_PC\_19056), and Wellcome Trust (Grant Ref:  
60 222406/Z/20/Z).

61 **Keywords:** COVID-19, corticosteroid, dexamethasone, mortality, clinical trial.

62

## Higher dose corticosteroids for COVID-19

### 63 INTRODUCTION

64 The RECOVERY trial has previously shown that the use of corticosteroids (using  
65 dexamethasone 6 mg once daily for ten days or until discharge if sooner) reduces the risk  
66 of death in patients admitted to hospital with COVID-19 and hypoxia.<sup>1</sup> Subsequent  
67 findings that additional immunosuppression with an interleukin-6 (IL-6) receptor blocker  
68 and/or a Janus kinase (JAK) inhibitor further reduces the risk of death in these patients  
69 raised the question whether simply increasing the dose of corticosteroid rather than  
70 adding other immunomodulators could confer additional benefits at substantially lower  
71 cost.<sup>2,3</sup>

72 In April 2021, the United Kingdom COVID-19 Therapeutics Advisory Panel recommended  
73 that the RECOVERY trial study higher dose of corticosteroids.<sup>4</sup> The RECOVERY trial  
74 therefore established a randomised evaluation of the effects of higher-dose  
75 corticosteroids versus usual care for adult patients who had been admitted to hospital  
76 with COVID-19 and had clinical evidence of hypoxia. Usual care for hypoxic COVID-19  
77 patients includes low dose corticosteroids. On 11 May 2022, the independent Data  
78 Monitoring Committee recommended that this comparison be halted for those patients  
79 receiving no oxygen or simple oxygen only on the grounds of safety and the results among  
80 such patients were published, showing that higher dose corticosteroids were associated  
81 with an increased 28-day mortality (123/659 [19%] in those allocated higher dose  
82 corticosteroids versus 75/613 [12%] in those allocated usual care, rate ratio 1.59; 95%  
83 confidence interval [CI] 1.20-2.10;  $p=0.0012$ ).<sup>5</sup> Recruitment of patients receiving  
84 ventilatory support continued.

## Higher dose corticosteroids for COVID-19

85 Trials of corticosteroids in non-COVID acute respiratory distress syndrome (ARDS) have  
86 not directly compared higher doses with the lower dose used in RECOVERY.<sup>6</sup> Higher  
87 doses of corticosteroids have been assessed in other trials among patients with COVID-  
88 19 receiving ventilatory support, but none have demonstrated clear benefit or harm.<sup>7-11</sup> A  
89 WHO meta-analysis of randomised controlled trials in critically ill COVID-19 indicated  
90 similar mortality benefit with lower and higher-dose corticosteroids, but estimates were  
91 imprecise.<sup>12</sup>

92 Here we report the results of the randomised comparison from the RECOVERY trial  
93 comparing higher dose corticosteroids with usual care among patients receiving  
94 ventilatory support.

95

## 96 **METHODS**

### 97 **Study design and participants**

98 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-  
99 initiated, individually randomised, controlled, open-label, platform trial to evaluate the  
100 effects of potential treatments in patients hospitalised with COVID-19. Details of the trial  
101 design and results for other possible treatments (dexamethasone, hydroxychloroquine,  
102 lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin,  
103 casirivimab plus imdevimab, baricitinib, higher-dose corticosteroids among patients not  
104 receiving ventilatory support, empagliflozin, molnupiravir and nirmatrelvir-ritonavir) have  
105 been published previously.<sup>1-3,5,13-21</sup> The trial was conducted at hospital organisations in

## Higher dose corticosteroids for COVID-19

106 the United Kingdom, supported by the National Institute for Health Research Clinical  
107 Research Network, as well as in South and Southeast Asia and Africa. Of these, 81  
108 hospitals in the UK, 5 in Nepal, 2 in Indonesia, 2 in Vietnam, 2 in South Africa, and 1 in  
109 Ghana enrolled participants in the evaluation of higher dose corticosteroids (appendix pp  
110 5-31). The trial was coordinated by the Nuffield Department of Population Health at the  
111 University of Oxford (Oxford, UK), the trial sponsor. The trial was conducted in  
112 accordance with the principles of the International Conference on Harmonisation–Good  
113 Clinical Practice guidelines. The protocol was approved by all relevant regulatory  
114 authorities and ethics committees in each participating country (appendix p 32) The  
115 protocol and statistical analysis plan are available in the appendix (pp 69-151) with  
116 additional information available on the study website [www.recoverytrial.net](http://www.recoverytrial.net).

117 Patients aged at least 18 years admitted to hospital were eligible for the study if they had  
118 clinically suspected or laboratory confirmed SARS-CoV-2 infection, clinical evidence of  
119 hypoxia (i.e. receiving oxygen with or without other forms of respiratory support, or with  
120 oxygen saturations <92% on room air) and no medical history that might, in the opinion  
121 of the attending clinician, put the patient at significant risk if they were to participate in the  
122 trial. Patients were ineligible for the comparison of higher dose corticosteroid vs. usual  
123 care if there was a known contra-indication to short-term use of corticosteroids, suspected  
124 or confirmed influenza, or current use of nirmatrelvir-ritonavir, ritonavir or other potent  
125 CYP3A inhibitors. Ventilatory support includes continuous positive airway pressure, bi-  
126 level positive airway pressure, high-flow nasal oxygen (together non-invasive ventilation),  
127 invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO).  
128 Endemic infections were screened for in accordance with local practice. Other

## Higher dose corticosteroids for COVID-19

129 immunomodulatory therapies were not contra-indicated but investigators were advised to  
130 consider the total burden of such therapy (e.g. combining an IL-6 receptor antagonist with  
131 higher dose corticosteroid). Written informed consent was obtained from all patients, or a  
132 legal representative if patients were too unwell or unable to provide consent.

### 133 **Randomisation and masking**

134 Baseline data were collected using a web-based case report form that included  
135 demographics, level of respiratory support, major comorbidities, suitability of the study  
136 treatment for a particular patient, SARS-CoV-2 vaccination status, and treatment  
137 availability at the study site (appendix pp 46).

138 Eligible and consenting patients were assigned in a 1:1 ratio to either usual standard of  
139 care plus higher dose corticosteroids or usual standard of care alone (which includes low  
140 dose corticosteroids, usually dexamethasone 6 mg once daily for 10 days or until  
141 discharge if sooner), using web-based simple (unstratified) randomisation with allocation  
142 concealed until after randomisation (appendix pp 41-5).<sup>22,23</sup> Patients allocated to higher  
143 dose corticosteroid were to receive dexamethasone 20 mg daily for 5 days followed by  
144 dexamethasone 10 mg for 5 days (or until discharge if sooner). Alternative corticosteroid  
145 regimens for pregnant women are described in the protocol (appendix p 69-111).

146 As a platform trial, and in a factorial design, patients could be simultaneously randomised  
147 to other treatment groups: i) empagliflozin versus usual care, ii) sotrovimab versus usual  
148 care, and iii) molnupiravir versus usual care. Further details of when these factorial  
149 randomisations were open are provided in the supplementary appendix (pp 41-3).  
150 Participants and local study staff were not masked to the allocated treatment. Other than

## Higher dose corticosteroids for COVID-19

151 members of the Data Monitoring Committee, all individuals involved in the trial were  
152 masked to aggregated outcome data while recruitment and 28-day follow-up were  
153 ongoing.

### 154 **Procedures**

155 An online follow-up form was completed by site staff when patients were discharged, had  
156 died, or at 28 days after randomisation, whichever occurred first (appendix pp 47-55).  
157 Information was recorded on adherence to allocated trial treatment, receipt of other  
158 COVID-19 treatments, duration of admission, receipt of respiratory or renal support, new  
159 cardiac arrhythmia, thrombosis, clinically significant bleeding, non-COVID infection,  
160 metabolic complications (collected from 28 July 2021 onwards), and vital status (including  
161 cause of death). In addition, in the UK, routinely collected healthcare and registry data  
162 were obtained, including information on vital status at day 28 (with date and cause of  
163 death); discharge from hospital; and receipt of respiratory support or renal replacement  
164 therapy. For sites outside the UK a further case report form (appendix p 56) collected vital  
165 status at day 28 (if not already reported on follow-up form).

### 166 **Outcomes**

167 Outcomes were assessed at 28 days after randomisation, with further analyses specified  
168 at 6 months. The primary outcome was 28-day all-cause mortality. Secondary outcomes  
169 were time to discharge from hospital, and, among patients not on invasive mechanical  
170 ventilation at randomisation (which for this report means those who are on non-invasive  
171 mechanical ventilation at randomisation), the composite outcome of invasive mechanical  
172 ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified



## Higher dose corticosteroids for COVID-19

173 subsidiary clinical outcomes were successful cessation of invasive ventilation among  
174 those receiving invasive ventilation at randomisation, use of invasive mechanical  
175 ventilation among patients not on non-invasive ventilation at randomisation, and use of  
176 renal dialysis or haemofiltration. Prespecified safety outcomes were cause-specific  
177 mortality, major cardiac arrhythmia, thrombotic and major bleeding events, other  
178 infections and metabolic complications. Information on suspected serious adverse  
179 reactions was collected in an expedited fashion to comply with regulatory requirements.  
180 Details of the methods used to ascertain and derive outcomes are provided in the  
181 appendix (pp 152).

### 182 **Sample size and role of the independent Data Monitoring Committee**

183 As stated in the protocol, appropriate sample sizes could not be estimated when the trial  
184 was being planned. However, the intention for this comparison was to continue  
185 recruitment until sufficient primary outcomes had accrued to have 90% power to detect a  
186 proportional risk reduction of 20% at  $2P=0.01$ .

187 The independent Data Monitoring Committee reviewed unblinded analyses of the study  
188 data and any other information considered relevant to the trial at intervals of around 2-3  
189 months (depending on speed of enrolment) and was charged with determining if, in their  
190 view, the randomised comparisons in the study provided evidence on mortality that was  
191 strong enough (with a range of uncertainty around the results that was narrow enough)  
192 to affect national and global treatment strategies (appendix p 58).

## Higher dose corticosteroids for COVID-19

193 On 11 May 2022, the Data Monitoring Committee recommended stopping recruitment to  
194 the higher dose corticosteroid comparison for patients who require no oxygen or simple  
195 oxygen only at randomisation due to safety concerns (appendix p 59). The Data  
196 Monitoring Committee encouraged continuing recruitment of all those patients who, at  
197 randomisation, require either non-invasive ventilation, invasive mechanical ventilation or  
198 ECMO. Recruitment continued until 31 March 2024 when funding for the trial ended.

### 199 **Statistical Analysis**

200 All analyses in this report were limited to the subgroup of patients receiving ventilatory  
201 support at randomisation. For all outcomes, intention-to-treat analyses compared patients  
202 randomised to higher dose corticosteroids with patients randomised to usual care. For  
203 the primary outcome of 28-day mortality, the HR from a Cox model with adjustment for  
204 age in three categories (<70 years, 70-79 years, and 80 years or older) and ventilation  
205 status at randomisation in two categories (non-invasive ventilation and invasive  
206 mechanical ventilation) was used to estimate the mortality rate ratio. We constructed  
207 Kaplan-Meier survival curves to display cumulative mortality over the 28-day period  
208 (starting on the day of randomisation and ending 28 days later). We used the same Cox  
209 regression method to analyse time to hospital discharge and successful cessation of  
210 invasive mechanical ventilation, with patients who died in hospital right-censored on day  
211 29. Median time to discharge was derived from Kaplan-Meier estimates. For the  
212 composite secondary outcome of progression to invasive mechanical ventilation or death  
213 within 28 days, and the subsidiary clinical outcomes of receipt of ventilation and use of  
214 haemodialysis or haemofiltration, the precise dates were not available and a log-binomial

## Higher dose corticosteroids for COVID-19

215 regression model was used to estimate the risk ratio (RR) adjusted for age and ventilation  
216 status. Estimates of rate and risk ratios (both denoted RR) are shown with 95%  
217 confidence intervals. For safety outcomes, unadjusted absolute risk differences were  
218 calculated as the difference in the proportions of patients experiencing outcomes by  
219 treatment allocation.

220 Since the analyses presented here relate only to the subset of participants who required  
221 ventilatory support at randomisation, any analyses of the primary outcome in further  
222 subgroups defined by different baseline characteristics must be considered exploratory  
223 in nature. With that caveat, we present analyses of the primary outcome by age, sex,  
224 ethnicity, country, days since symptom onset, and respiratory support received with tests  
225 of heterogeneity or trend, as appropriate. We have not presented analyses by subgroups  
226 for the secondary or other outcomes. Results for the pre-specified other clinical outcomes  
227 and safety outcomes are presented. For the primary outcome of 28-day mortality, the  
228 results from RECOVERY were subsequently included in a meta-analysis of results from  
229 all previous randomised trials of higher vs lower dose steroids in patients with COVID-19.  
230 For each trial, we compared the observed number of deaths among patients allocated  
231 higher dose steroids with the expected number if all patients were at equal risk (ie, we  
232 calculated the observed minus expected statistic  $[o-e]$ , and its variance  $v$ ). For the  
233 previously-reported RECOVERY findings in lower risk (not on ventilation) patients, these  
234 were taken as the log-rank observed minus expected statistic and its variance but for  
235 other trials, where the exact timing of each death was not available, these were calculated  
236 from standard formulae for  $2 \times 2$  contingency tables. We then combined trial results using  
237 the log of the mortality rate ratio calculated as the inverse-variance weighted average  $S/V$

## Higher dose corticosteroids for COVID-19

238 with variance  $1/V$  (and hence with 95% CI  $S/V \pm 1.96/\sqrt{V}$ ), where  $S$  is the sum over all  
239 trials of  $(O-E)$  and  $V$  is the sum over all trials of  $v$ . The full database is held by the study  
240 team which collected the data from study sites and performed the analyses at the Nuffield  
241 Department of Population Health, University of Oxford (Oxford, UK). Analyses were  
242 performed using SAS version 9.4 and R version 4.0.3. The trial is registered with ISRCTN  
243 (50189673) and [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04381936).

### 244 **Role of the funding source**

245 The funders of the study had no role in study design, data collection, data analysis, data  
246 interpretation, or writing of the report. The corresponding authors had full access to all the  
247 data in the study and had final responsibility for the decision to submit for publication.

248

### 249 **RESULTS**

250 Recruitment to the evaluation of higher dose corticosteroids commenced on 25 May 2021  
251 outside the UK and 29 December 2021 in the UK (following closure of the baricitinib  
252 comparison) and ended worldwide on 31 March 2024 (last participant randomised on 9  
253 January 2024). Of 1749 patients enrolled in this comparison during this period, 477  
254 patients receiving ventilatory support are included in this evaluation. Of these, 246 were  
255 randomly allocated to higher dose corticosteroids and 231 patients were randomly  
256 allocated to usual care (Figure 1). The mean age of these participants was 61.4 years  
257 (SD 15.5), 221 (46%) were recruited in Asia, 245 (51%) in the UK and 11 (2%) in Africa.

## Higher dose corticosteroids for COVID-19

258 411 (86%) were receiving non-invasive ventilation and 66 (14%) were receiving invasive  
259 mechanical ventilation. 143 (30%) had a history of diabetes mellitus (Table 1).

260 The follow-up form was completed for 246 (100%) patients in the higher dose  
261 corticosteroid group and 229 (99.1%) patients in the usual care group. Among patients  
262 with a completed follow-up form, 87% allocated to higher dose corticosteroid were  
263 reported to have received higher dose corticosteroids compared with 6% allocated to  
264 usual care (figure 1, webtable 2). Among those with a completed follow-up form allocated  
265 usual care, 68% received low dose and 18% received intermediate dose (>6 <20 mg)  
266 dexamethasone. 39% received remdesivir, 15% received an interleukin-6 antagonist and  
267 5% received baricitnib during the follow-up period (webtable 2).

268 Primary and secondary outcome data are known for >99% of randomly assigned patients.  
269 Allocation to higher dose corticosteroids was associated with a non-significant reduction  
270 in the primary outcome of 28-day mortality compared with usual care alone: 86 (35%) of  
271 246 patients in the higher dose corticosteroid group died vs 86 (37%) of 231 patients in  
272 the usual care group (rate ratio 0.87; 95% CI 0.64-1.18; p=0.37; table 2, figure 2). In  
273 exploratory analyses, there was no good evidence that the proportional effect of higher  
274 dose corticosteroids on mortality differed across all 5 pre-specified subgroups, nor in an  
275 exploratory analysis by country (Figure 3). In another exploratory analysis (data not  
276 shown), there was also no good evidence of heterogeneity according to baseline use (or  
277 planned use) of tocilizumab.

278 Discharge alive within 28 days was similar among those allocated to higher dose  
279 corticosteroids compared with usual care (52% vs. 52%; rate ratio 1.04, 95% CI 0.81 to

## Higher dose corticosteroids for COVID-19

280 1.33; median 24 days vs. 26 days) (table 2). Among participants not on invasive  
281 mechanical ventilation (i.e. on non-invasive ventilation) at randomisation, allocation to  
282 higher dose corticosteroids was associated with a non-significant reduction in the risk of  
283 progressing to the composite secondary outcome of invasive mechanical ventilation or  
284 death (37% vs. 45%, risk ratio 0.79, 95% CI 0.63 to 1.00) (table 2). There were no  
285 significant differences in use of invasive mechanical ventilation amongst patients on non-  
286 invasive ventilation at randomisation, or receipt of haemodialysis or haemofiltration (table  
287 2).

288 137 (80%) of the deaths within 28 days were attributed to COVID-19 (webtable 3).  
289 Allocation to higher dose corticosteroids was associated with a non-significant increase  
290 in secondary infections (29% vs. 21%, absolute risk increase 7.6%, 95% CI -0.1 to 15.4%;  
291 webtable 4) including pneumonia reported as not due to COVID-19 (21% vs. 14%,  
292 absolute risk increase 6.4%, 95% CI -0.3 to 13.2%). There were no significant differences  
293 in the rates of other presentations of new onset cardiac arrhythmia, thrombotic events,  
294 clinically significant bleeding or metabolic complications (including hyperglycaemia  
295 receiving new use of insulin) (webtable 4). There were 32 reports (among 19 participants)  
296 of a serious adverse reaction believed to be related to treatment with higher dose  
297 corticosteroids (webtable 5), including 15 reports of a serious non-COVID infection, 5 with  
298 hyperglycaemia and 4 with gastro-intestinal bleeding.

299 Our meta-analysis identified 142 deaths among 657 participants in 5 other trials  
300 assessing higher dose corticosteroids among patients requiring ventilation (webfigure 1).  
301 Our results appeared to be consistent with the other limited data and overall there was

## Higher dose corticosteroids for COVID-19

302 no evidence that higher-dose corticosteroids were beneficial in these patients (overall  
303 ratio of death rates 0.87, 95% CI 0.69-1.11).

304

### 305 **DISCUSSION**

306 In this randomised trial among patients with COVID-19 receiving ventilatory support, we  
307 found no evidence that allocation to higher dose corticosteroids reduced 28-day mortality,  
308 duration of hospitalization or, among patients not on invasive mechanical ventilation at  
309 baseline, the composite outcome of use of invasive mechanical ventilation or death.

310 The non-significant reductions observed in this population of patients contrast with the  
311 significant hazards observed among patients not receiving ventilatory support reported  
312 previously.<sup>5</sup> There is statistical heterogeneity ( $p=0.007$ ) between the estimates of the  
313 effect of allocation to higher dose corticosteroids on 28 day mortality in these two  
314 populations: 0.87 (95% CI 0.64-1.18) among patients receiving ventilatory supported  
315 versus 1.59 (95% CI 1.20-2.10) among those not. It is possible that the reported result  
316 among patients not receiving ventilatory support is an over-estimate of the true effect  
317 because it was based on an interim analysis, and therefore the true heterogeneity  
318 between these two populations may not be so marked.<sup>24</sup> Although there is clear evidence  
319 of effect modification by baseline disease severity with low-dose corticosteroids,<sup>1</sup> the  
320 subgroup analysis within the comparison reported here does not suggest that there is  
321 increasing benefit with increasing severity of disease with if anything the reverse being  
322 seen, albeit based on a very small number of outcomes.

## Higher dose corticosteroids for COVID-19

323 Results from RECOVERY and other trials have shown that combining immunomodulatory  
324 therapies can provide additional benefit with both tocilizumab and baricitinib providing  
325 additional benefits over low-dose corticosteroids.<sup>3,25</sup> These drugs are not widely available  
326 nor affordable in low- and middle-income countries whereas higher doses of  
327 corticosteroids are. However, we found no evidence that higher doses of corticosteroids  
328 were beneficial, even in the absence of tocilizumab, so our results do not support their  
329 use as a more affordable option where such therapies are not available.

330 There was a non-significant excess of secondary infections in this comparison (absolute  
331 risk increase 7.7%, 95% CI -0.1 to 15.4). The proportional increase of about one-third  
332 was similar to that observed among patients not requiring ventilatory support, so when  
333 considered in combination it is clear that higher dose corticosteroids are associated with  
334 more infections than usual care that includes low dose corticosteroids. However, the  
335 excess of hyperglycaemia requiring new use of insulin reported among patients not  
336 receiving ventilatory support was not observed in this population, but this may have been  
337 a chance finding as it is based on fewer than 100 events.

338 Strengths of the RECOVERY trial are that it is randomised, has a large sample size, broad  
339 eligibility criteria and more than 99% of patients in this analysis have been followed up for  
340 the primary outcome. The trial was also conducted in areas with high (south and  
341 southeast Asia, and Africa) and low (UK) prevalence of tuberculosis and other infections.  
342 The study has some limitations: this randomised trial is open label (i.e., participants and  
343 local hospital staff are aware of the assigned treatment), however, the outcome of death



## Higher dose corticosteroids for COVID-19

344 is unambiguous. Information on radiological, virological or physiological outcomes were  
345 not collected.

346 In summary, the results provide no evidence that in hypoxic COVID-19 patients receiving  
347 ventilatory support, a higher dose of corticosteroids (dexamethasone 20 mg once daily  
348 for 5 days followed by 10 mg once daily for 5 days or until discharge if sooner) provides  
349 additional benefit over low-dose corticosteroids which should remain the standard of care  
350 for such patients.

351

## Higher dose corticosteroids for COVID-19

### 352 **Contributors**

353 This manuscript was initially drafted by RH, further developed by the Writing Committee,  
354 and approved by all members of the Trial Steering Committee. PWH and MJL vouch for  
355 the data and analyses, and for the fidelity of this report to the study protocol and data  
356 analysis plan. PWH, BB, RLH, JA, JKB, MB, LCC, JD, SNF, TJ, EJ, KJ, WSL, MM, AMo,  
357 AMu, KR, GT, RH, and MJL designed the trial and study protocol. MM, LP, MC, G P-A,  
358 EK, NTP, AS, NN, RS, PNT, DP, US, RS, EN, MR and the Data Linkage team at the  
359 RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff  
360 listed in the appendix collected the data. NS and JRE had access to the study data and  
361 did the statistical analysis. All authors contributed to data interpretation and critical review  
362 and revision of the manuscript. PWH and MJL had access to the study data and had final  
363 responsibility for the decision to submit for publication.

### 364 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

365 Peter W Horby\*, Jonathan R Emberson\*, Louise Thwaites\*, Mark Campbell, Leon Peto,  
366 Guilherme Pessoa-Amorim, Natalie Staplin, Raph L Hamers, John Amuasi, Jeremy Nel,  
367 Evelyne Kestelyn, Nguyen Thanh Phong, Anil Shrestha, Nasronudin Nasronudin,  
368 Rahuldeb Sarkar, Pham Ngoc Thach, Damodar Paudel, Uun Sumardi, Richard Stewart,  
369 Erni Nelwan, Manisha Rawal, J Kenneth Baillie, Maya H Buch, Saul N Faust, Thomas  
370 Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Marion Mafham,  
371 Alan Montgomery, Andrew Mumford, Kathryn Rowan, Buddha Basnyat<sup>†</sup>, Richard  
372 Haynes<sup>†</sup>, Martin J Landray<sup>†</sup>

373 \* PWH, JRE and GT made an equal contribution

374 + BB, RH and MJL made an equal contribution

### 375 **Data Monitoring Committee**

376 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,  
377 Mohammed Munavvar, Adilia Warris, Janet Wittes.

378

## Higher dose corticosteroids for COVID-19

### 379 **Declaration of interests**

380 The authors have no conflict of interest or financial relationships relevant to the submitted  
381 work to disclose. No form of payment was given to anyone to produce the manuscript. All  
382 authors have completed and submitted the ICMJE Form for Disclosure of Potential  
383 Conflicts of Interest. The Nuffield Department of Population Health at the University of  
384 Oxford has a staff policy of not accepting honoraria or consultancy fees directly or  
385 indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-independence-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)  
386 [of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

### 387 **Data sharing**

388 The protocol, consent form, statistical analysis plan, definition & derivation of clinical  
389 characteristics & outcomes, training materials, regulatory documents, and other relevant  
390 study materials are available online at [www.recoverytrial.net](http://www.recoverytrial.net). As described in the protocol,  
391 the Trial Steering Committee will facilitate the use of the study data and approval will not  
392 be unreasonably withheld. Deidentified participant data will be made available to bona  
393 fide researchers registered with an appropriate institution within 3 months of publication.  
394 However, the Steering Committee will need to be satisfied that any proposed publication  
395 is of high quality, honours the commitments made to the study participants in the consent  
396 documentation and ethical approvals, and is compliant with relevant legal and regulatory  
397 requirements (e.g. relating to data protection and privacy). The Steering Committee will  
398 have the right to review and comment on any draft manuscripts prior to publication. Data  
399 will be made available in line with the policy and procedures described at:  
400 <https://www.ndph.ox.ac.uk/data-access>. Those wishing to request access should  
401 complete the form at  
402 [https://www.ndph.ox.ac.uk/files/about/data\\_access\\_enquiry\\_form\\_13\\_6\\_2019.docx](https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx)  
403 and e-mailed to: [data.access@ndph.ox.ac.uk](mailto:data.access@ndph.ox.ac.uk)

404

## Higher dose corticosteroids for COVID-19

### 405 **Acknowledgements**

406 Above all, we would like to thank the thousands of patients who participated in this trial.  
407 We would also like to thank the many doctors, nurses, pharmacists, other allied health  
408 professionals, and research administrators at participating hospital organisations.  
409 Supported in the UK by staff at the National Institute of Health Research (NIHR) Clinical  
410 Research Network, NHS DigiTrials, Public Health England, Department of Health & Social  
411 Care, the Intensive Care National Audit & Research Centre, Public Health Scotland,  
412 National Records Service of Scotland, the Secure Anonymised Information Linkage  
413 (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and Northern  
414 Ireland.

415 The RECOVERY trial is supported by grants to the University of Oxford from UK Research  
416 and Innovation (UKRI) and NIHR (MC\_PC\_19056), the Wellcome Trust (Grant Ref:  
417 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding  
418 provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill  
419 and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office,  
420 Health Data Research UK, the Medical Research Council, the NIHR Health Protection  
421 Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding.  
422 TJ is supported by a grant from UK Medical Research Council (MC\_UU\_00002/14). WSL  
423 is supported by core funding provided by NIHR Nottingham Biomedical Research Centre.  
424 Tocilizumab, casirivimab and imdevimab, sotrovimab, and empagliflozin were provided  
425 through support from Roche, Regeneron, GSK, and Boehringer Ingelheim, respectively.  
426 Colchicine for use in Indonesia was provided by Combiphar. The views expressed in this  
427 publication are those of the authors and not necessarily those of the NHS, the NIHR or  
428 the Department of Health and Social Care. For the purpose of Open Access, the author  
429 has applied a CC BY public copyright licence to any Author Accepted Manuscript version  
430 arising from this submission.

431

432

## Higher dose corticosteroids for COVID-19

### 433 References

- 434 1. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in  
435 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
- 436 2. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital  
437 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
438 *Lancet* 2021; **397**(10285): 1637-45.
- 439 3. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with  
440 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and  
441 updated meta-analysis. *Lancet* 2022; **400**(10349): 359-68.
- 442 4. UK Research and Innovation. 13 April 2021 UK-CTAP: record of decisions. 2021.  
443 [https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-](https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-decisions/13-april-2021-uk-ctap-record-of-decisions/)  
444 [decisions/13-april-2021-uk-ctap-record-of-decisions/](https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-decisions/13-april-2021-uk-ctap-record-of-decisions/) (accessed 16 September 2022).
- 445 5. RECOVERY Collaborative Group. Higher dose corticosteroids in patients  
446 admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory  
447 support (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*  
448 2023; **401**(10387): 1499-507.
- 449 6. Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute  
450 respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir*  
451 *Med* 2020; **8**(3): 267-76.
- 452 7. Wu H, Daouk S, Kebbe J, Chaudry F, Harper J, Brown B. Low-dose versus high-  
453 dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A  
454 randomized clinical trial. *PloS one* 2022; **17**(10): e0275217.
- 455 8. Soliman OM, Moeen SM, Abbas YA, Kamel EZ. The impact of dexamethasone  
456 versus methylprednisolone upon neutrophil/lymphocyte ratio in COVID-19 patients  
457 admitted to ICU and its implication upon mortality. *Egyptian Journal of Anaesthesia*  
458 2022; **38**(1): 78-84.
- 459 9. Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone  
460 pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind,  
461 randomised, placebo-controlled trial. *Eur Respir J* 2022; **60**(4).
- 462 10. Maskin LP, Bonelli I, Olarte GL, et al. High- Versus Low-Dose Dexamethasone  
463 for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A  
464 Multicenter, Randomized Open-Label Clinical Trial. *J Intensive Care Med* 2022; **37**(4):  
465 491-9.
- 466 11. Salton F, Confalonieri P, Centanni S, et al. Prolonged higher dose  
467 methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a  
468 randomised controlled trial (MEDEAS). *The European respiratory journal* 2022; **10**.

## Higher dose corticosteroids for COVID-19

- 469 12. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne  
470 JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids  
471 and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 2020;  
472 **324**(13): 1330-41.
- 473 13. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of  
474 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;  
475 **383**(21): 2030-40.
- 476 14. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-  
477 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,  
478 controlled, open-label, platform trial. *Lancet* 2020; **396**(10259 ): 1345-52.
- 479 15. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital  
480 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
481 *Lancet* 2021; **397**(10274): 605-12.
- 482 16. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to  
483 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform  
484 trial. *Lancet* 2021; **397**(10289): 2049-59.
- 485 17. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with  
486 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The*  
487 *Lancet Respiratory Medicine* 2021.
- 488 18. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with  
489 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*  
490 2022; **399**(10320): 143-51.
- 491 19. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients  
492 admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-  
493 label, platform trial. *Lancet* 2022; **399**(10325): 665-76.
- 494 20. RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital  
495 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
496 *Lancet Diabetes Endocrinol* 2023; **11**(12): 905-14.
- 497 21. RECOVERY Collaborative Group. Molnupiravir or nirmatrelvir-ritonavir versus  
498 usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,  
499 controlled, open-label, platform trial. *medRxiv* 2024.
- 500 22. World Health Organization. Update to living WHO guideline on drugs for covid-  
501 19. *BMJ* 2021; **372**: n860.
- 502 23. National Institute for Health and Care Excellence. COVID-19 rapid guideline:  
503 Managing COVID-19., 2022.

## Higher dose corticosteroids for COVID-19

- 504 24. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit  
505 and estimation of treatment effects: systematic review and meta-regression analysis.  
506 *JAMA* 2010; **303**(12): 1180-7.
- 507 25. The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group.  
508 Association Between Administration of IL-6 Antagonists and Mortality Among Patients  
509 Hospitalized for COVID-19: A Meta-analysis. *Jama* 2021; **326**(6): 499-518.
- 510

**Table 1: Baseline characteristics by treatment allocation**

	<b>Higher dose steroids (n=246)</b>	<b>Usual care (n=231)</b>
Age, years	61.7 (14.9)	61.1 (16.1)
<70	164 (67%)	157 (68%)
≥70 to <80	61 (25%)	46 (20%)
≥80	21 (9%)	28 (12%)
Sex		
Male	147 (60%)	151 (65%)
Female	99 (40%)	80 (35%)
Country		
Indonesia	28 (11%)	37 (16%)
Nepal	44 (18%)	42 (18%)
South Africa	8 (3%)	3 (1%)
Vietnam	40 (16%)	30 (13%)
United Kingdom	126 (51%)	119 (52%)
Ethnicity		
White	107 (43%)	96 (42%)
Black	1 (<0.5%)	5 (2%)
Asian	77 (31%)	87 (38%)
Other	4 (2%)	3 (1%)
Unknown	57 (23%)	40 (17%)
Number of days since symptom onset	8 (5-12)	7 (5-12)
Number of days since admission to hospital	2 (1-4)	2 (1-4)
Respiratory support received		
Non-invasive ventilation	206 (84%)	205 (89%)
Invasive mechanical ventilation	40 (16%)	26 (11%)
Previous diseases		
Diabetes	74 (30%)	69 (30%)
Heart disease	77 (31%)	69 (30%)
Chronic lung disease	57 (23%)	46 (20%)
Tuberculosis	1 (<0.5%)	2 (1%)
HIV	4 (2%)	1 (<0.5%)
Severe liver disease *	7 (3%)	4 (2%)
Severe kidney impairment †	22 (9%)	14 (6%)
Any of the above	159 (65%)	134 (58%)
SARS-CoV-2 test result		
Positive	232 (94%)	213 (92%)
Negative	2 (1%)	3 (1%)
Unknown	12 (5%)	15 (6%)
Received a COVID-19 vaccine	133 (54%)	112 (48%)
Use of other treatments		
Remdesivir	88 (36%)	78 (34%)
Tocilizumab	57 (23%)	51 (22%)
Plan to use tocilizumab within the next 24 hours	23 (9%)	17 (7%)

Data are mean (SD), n (%), or median (IQR). 0 pregnant women were randomised. \* Defined as requiring ongoing specialist care.  
 † Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m<sup>2</sup>



**Table 2: Effect of allocation to higher dose corticosteroid on key study outcomes**

	Treatment allocation		RR (95% CI)
	Higher dose steroids (n=246)	Usual care (n=231)	
<b>Primary outcome</b>			
28-day mortality	86 (35%)	86 (37%)	0.87 (0.64-1.18)
<b>Secondary outcomes</b>			
Time to being discharged alive, days	24 (12 to >28)	26 (11 to >28)	
Discharged from hospital within 28 days	128 (52%)	120 (52%)	1.04 (0.81-1.33)
Receipt of invasive mechanical ventilation or death*	76/206 (37%)	93/205 (45%)	0.79 (0.63-1.00)
Invasive mechanical ventilation	29/206 (14%)	40/205 (20%)	0.72 (0.46-1.11)
Death	65/206 (32%)	79/205 (39%)	0.80 (0.62-1.04)
<b>Subsidiary clinical outcomes</b>			
Successful cessation of invasive mechanical ventilation †	14/40 (35%)	11/26 (42%)	0.80 (0.36-1.80)
Use of haemodialysis or haemofiltration ‡	21/243 (9%)	18/229 (8%)	0.97 (0.54-1.74)

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for other outcomes. CI=confidence interval. Estimates of the RR and its 95% CI are adjusted for age in three categories (<70 years, 70-79 years, and 80 years or older) and ventilation status at randomisation in two categories (non-invasive ventilation and invasive mechanical ventilation). \* Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses restricted to those on invasive mechanical ventilation at randomisation. ‡ Analyses exclude those on haemodialysis or haemofiltration at randomisation.

## Figures

### Figure 1: Trial profile

ITT=intention to treat. Higher dose corticosteroid unavailable and higher dose corticosteroid considered unsuitable are not mutually exclusive. High risk patients are those that were receiving non-invasive ventilation, invasive mechanical ventilation or ECMO at randomisation. Low risk patients are those that were hypoxic but receiving no oxygen or simple oxygen only. \* Number recruited overall during period that participants on no oxygen or simple oxygen only could be recruited into the higher dose corticosteroid comparison.

### Figure 2: Effect of allocation to higher dose corticosteroids or usual care (lower dose corticosteroids) on 28-day mortality in patients receiving ventilatory support


RR = rate ratio

### Figure 3: Effect of allocation to higher dose corticosteroids or usual care (lower dose corticosteroids) on 28-day mortality in patients receiving ventilatory support by other baseline characteristics.

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The days since onset subgroup excludes those with missing data, but these patients are included in the overall summary diamond. RR=rate ratio.


# Figure 1: Trial profile

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.04.24312992>; this version posted September 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



## Figure 2: Effect of allocation to higher dose steroids vs usual care (lower dose steroids) on 28-day mortality in patients receiving non-invasive or invasive mechanical ventilation

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.06.24312992>; this version posted September 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Number at risk	0	7	14	21	28
Higher dose steroids	246	212	189	169	160
Usual care	231	190	164	153	144

**Figure 3: Effect of allocation to higher dose steroids vs usual care (lower dose steroids) on 28-day mortality in patients receiving non-invasive or invasive mechanical ventilation, by other baseline characteristics**

